Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.
Tag: GLP-1 receptor agonists
SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective
A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.
Study: Antidiabetic drug causes double the weight loss of competitor in Type 2 diabetes patients
Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study.